Genetic alterations of HLA-class II in ovarian cancer

International Journal of Cancer

Volumn 123, Issue 6, 2008, Pages 1350-1356

  Kübler, Kirsten ^a   Arndt, Peter F ^b   Wardelmann, Eva ^a   Landwehr, Christina ^a   Krebs, Dieter ^a   Kuhn, Walther ^a   Van Der Ven, Katrin ^a  

^a UNIVERSITY OF BONN   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

CGH; Genetic alterations; HLA antigen expression; HLA class II; Ovarian cancer

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DQB1 ANTIGEN; HLA DR ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER IMMUNOLOGY; CHROMOSOME 6P; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HLA SYSTEM; HOST RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IMMUNOPATHOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; ONCOGENE; OVARY CANCER; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADULT; AGED; FEMALE; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; OVARIAN NEOPLASMS; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 49749115805     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23624     Document Type: Article

References (48)

1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
2. Salih HR, Nussler V. Commentary: immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res 2001;6:323-32.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
5. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-43.
6. Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA, Schwartzentruber DJ. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am 1996;2:263.
7. Matsushita N, Ghazizadeh M, Konishi H, Araki T. Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes. J Nippon Med Sch 2003;70:40-4.
8. Kabawat SE, Bast RC, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer 1983;32:547-54.
9. Tamiolakis D, Kotini A, Venizelos J, Jivannakis T, Simopoulos C, Papadopoulos N. Prognostic significance of HLA-DR antigen in serous ovarian tumors. Clin Exp Med 2003;3:113-8.
10. Möbus VJ, Asphal W, Knapstein PG, Kreienberg R. Effects of interferon gamma on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 1993;120:27-34.
11. Nash MA, Lenzi R, Edwards CL, Kavanagh JJ, Kudelka AP, Verschraegen CF, Platsoucas CD, Freedman RS. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established cell lines. Clin Exp Immunol 1998;112:172-80.
12. Jo YS, Lee JC, Li S, Choi YS, Bai YS, Kim YJ, Lee IS, Rha SY, Ro HK, Kim JM, Shong M. Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer. Int J Cancer 2008;122:785-90.
13. Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990;144:4068-71.
14. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specifity. Nat Genet 1994;6:157-62.
15. Lee JE, Reveille JD, Ross MI, Platsoucas CD. HLA-DQB*0301 association with increased cutaneous melanoma risk. Int J Cancer 1994;59:510-3.
16. Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, Finkelstein D, Forcione D, Pillai S. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci USA 2000;97:11451-4.
17. Koskinen WJ, Partanen J, Vaheri A, Aaltonen LM. HLA-DRB1, -DQB1 alleles in head and neck carcinoma patients. Tissue Antigens 2006;67:237-40.
18. Kübler K, Arndt PF, Wardelmann E, Krebs D, Kuhn W, van der Ven K. HLA-class II haplotype associations with ovarian cancer. Int J Cancer 2006;119:2980-5.
19. Benedet JL, Bender H, Jones III H, Ngan HYS, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 2000;70:209-62.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
21. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and HLA-DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993;41:119-34.
22. Ziegler A, Field LL, Sakaguchi AY. Report of the committee on the genetic constitution of chomosome 6. Cytogenet Cell Genet 1991;58:295-336.
23. van der Ven K, Ober C. HLA-G polymorphisms in African Americans. J Immunol 1994;153:5628-33.
24. Voorter C, Richeldi L, Gervais T, van den Berg-Loonen E. Identification of two new DPB1 alleles, DPB1*7701 and *7801, by sequence-based typing. Tissue Antigens 1998;52:190-2.
25. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005;11:6116-26.
26. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ. de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
27. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg->Gln mutation in the gene for factor V. N Engl J Med 1994;331:1559-62.
28. van der Ven K, Montag M, Peschka B, Leygraaf J, Schwanitz G, Haidl G, Krebs D, van der Ven H. Combined cytogenetic and Y chromosome microdeletion screening in males undergoing intracytoplasmatic sperm injection. Mol Hum Reprod 1997;3:699-704.
29. Weber RG, Sommer C, Albert FK, Kiessling M, Cremer T. Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization. Lab Invest 1996;74:108-19.
30. Manoir du S, Schrock E, Bentz M, Speicher MR, Joos S, Ried T, Lichter P, Cremer T. Quantitative analysis of comparative genomic hybridization. Cytometry 1995;19:27-41.
31. De Zen L, Orfao A, Cazzaniga G, Masiero L, Cocito MG, Spinelli M, Rivolta A, Biondi A, Zanesco L, Basso G. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. 1. ETV6/AMLI ALLs identification. Leukemia 2000;14:1225-31.
32. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
33. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Geraghty DE, Hansen JA, Hurley CK, Mach B, Mayr WR, Parham P, et al. Nomenclature for factors of the HLA system, 2004. Hum Immunol 2005;66:571-636.
34. Begovich AB, McClure GR, Suraj VC, Helmuth RC, Fildes N, Bugawan TL, Erlich HA, Klitz W. Polymorphism, recombination, and linkage desiquilibrium within the HLA class II region. J Immunol 1992;148:249-58.
35. Partheen K, Levan K, Osterberg L, Helou K, Horvath G. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer 2004;40:342-8.
36. Hauptmann S, Denkert C, Koch I, Petersen S, Schlüns K, Reles A, Dietel M, Petersen I. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 2002;33:632-41.
37. Arnold N, Hagele L, Walz L, Schempp W, Pfisterer J, Bauknecht T, Kiechle M. Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. Genes Chromosomes Cancer 1996;16:46-54.
38. Santos GC, Zielenska M, Prasad M, Squire JA. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007;60:1-7.
39. Gamzatova Z, Villabona L, van der Zanden H, Haasnoot GW, Andersson E, Kiessling R, Seliger B, Kanter L, Dalianis T, Bergfeldt K, Masucci GV. Analysis of HLA class 1-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. Tissue Antigens 2007;70:205-13.
40. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996;93:1493-5.
41. Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 2002;97:163-7.
42. Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, Li F, Dewhirst MW, Li CY. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res 2006;66:11565-70.
43. Di Bello M, Lucchini V, Chiari S, Colleoni R, Colombo N, Mantovani A, Allavena P. DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response. Cancer Immunol Immunother 1988;27:63-8.
44. Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996;174:116-28.
45. Nijman HW, van Diest PJ, Poort-Keesom RJ, von Mensdorff-Pouilly S, Verstraeten RA, Kummer A, Meijer CJ, Melief CJ, Hilgers J, Kenemans P. T cell infiltration and MHC 1 and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2001;94:114-20.
46. Bernards R, Dessain SK, Weinerg RA. N-myc amplification causes down-modulation of MHC-class I antigen expression in neuroblastoma. Cell 1986;47:667-74.
47. Versteeg R, van der Minne C, Plomp A, Sijts A, van Lccuwen A, Schrier P. N-myc expression switched off and HLA-class I human leucocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells. Mol Cell Biol 1990;10:5416-23.
48. van't Veer LJ, Beijersbergen RL, Bernards R. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. EMBO J 1993;12:195-200.